Education
About Us
Working with TipRanks
Follow Us
PTC Therapeutics (PTCT)
NASDAQ:PTCT
Earnings Data
Report Date
Apr 24, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-1.02Last Year’s EPS
-1.2Same Quarter Last Year
Moderate Buy
Based on 12 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 27, 2025
|% Change Since: 12.77%
|Next Earnings Date:Apr 24, 2025
Earnings Call Sentiment|Positive
PTC Therapeutics had a strong 2024 with notable financial performance, successful regulatory achievements, and strategic partnerships. However, there are challenges and uncertainties in regulatory approvals and market conditions that may impact future performance.Company Guidance
During the PTC Therapeutics fourth quarter and full-year 2024 earnings call, the company reported exceeding its revenue guidance with a total of $807 million in revenue for the year, including $213 million in the fourth quarter. The company ended the year with over $1.1 billion in cash, bolstered by an additional $1 billion received in January 2025 from the Novartis PTC-518 transaction. Looking ahead to 2025, PTC anticipates several key milestones, including multiple potential commercial launches and regulatory decisions in the US and globally. They have set a revenue guidance range of $600 million to $800 million for 2025. The company also highlighted successful clinical and regulatory achievements in 2024, with FDA approval of KEBILIDI for AADC deficiency and several other submissions under review. Additionally, PTC announced a collaboration with Novartis for the PTC518 Huntington's disease program, which includes up to $1.9 billion in potential development and sales milestones.Strong Financial Performance
Fourth quarter revenue totaled $213 million, and full year 2024 revenue was $807 million, exceeding guidance. The company ended 2024 with over $1.1 billion in cash and received an additional $1 billion in January from the Novartis transaction.
Successful Regulatory Milestones
PTC submitted four approval applications to the FDA, all accepted for review, including KEBILIDI, Sepiapterin, Translarna, and Vatiquinone. KEBILIDI was approved in November.
Strategic Partnership with Novartis
PTC announced a collaboration with Novartis for the PTC518 Huntington's disease program, receiving $1 billion upfront and is eligible for up to $1.9 billion in development and sales milestones.
Exciting Prospects for 2025
PTC anticipates global launch of Sepiapterin, potential launch of Vatiquinone, and 12-month results from PIVOT-HD study.
---
PTCT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
PTCT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 27, 2025 | $50.57 | $55.26 | +9.27% |
| Nov 07, 2024 | $42.96 | $44.28 | +3.07% |
| Aug 08, 2024 | $32.45 | $31.29 | -3.57% |
| Apr 25, 2024 | $25.49 | $28.57 | +12.08% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does PTC Therapeutics (PTCT) report earnings?
PTC Therapeutics (PTCT) is schdueled to report earning on Apr 24, 2025, TBA Not Confirmed.
What is PTC Therapeutics (PTCT) earnings time?
PTC Therapeutics (PTCT) earnings time is at Apr 24, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PTCT EPS forecast?
PTCT EPS forecast for the fiscal quarter 2025 (Q1) is -1.02.
---